Navigation Links
ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohn's Disease
Date:6/12/2008

ary efficacy endpoint in the induction phase of the study is the attainment of a clinical response defined as a decrease from baseline in the Crohn's Disease Activity Index (CDAI) score of at least 70 points. In a separate clinical trial, Traficet-EN is also being evaluated for patients with celiac disease, a sensitivity to gluten and gluten derivatives in which digestive tract T cells are thought to play an important role.

"We are very pleased to have completed enrollment of more than 430 patients for the PROTECT-1 study at clinical sites in 17 countries worldwide. This represents an important milestone in the development of this promising new drug, as well as an impressive accomplishment by a committed group of investigators throughout the world and our entire clinical team," said Pirow Bekker, M.D., Ph.D., Vice President, Medical and Clinical Affairs of ChemoCentryx. "Following completion of PROTECT-1, our goal is to expeditiously advance additional clinical development of Traficet-EN to support regulatory filings worldwide."

ChemoCentryx's Second-Generation CCR9 Program

ChemoCentryx is also advancing a second-generation, orally-active CCR9 antagonist through preclinical development and anticipates a regulatory filing to enable first-in-human studies on this compound in the second half of the year. Structurally diverse from Traficet-EN, this second-generation CCR9 antagonist strengthens ChemoCentryx's proprietary position in the CCR9 arena, and gives the company the potential to pursue additional gastrointestinal and other clinical indications with discrete compounds.

The CCR9 program is a part of a strategic alliance that ChemoCentryx signed in 2006 with GlaxoSmithKline's Center of Excellence for External Drug Discovery (CEEDD) for the discovery and development of small molecule antagonists targeting four defined chemokine and chemoattractant receptors. Under the terms of the agreement, ChemoCentryx is responsible for advancing produc
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354
2. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
5. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
6. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
7. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
8. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
9. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
10. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
11. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 11, 2014 According to a ... Devices Market (Endoscopes, Endoscopic Operative Devices, and Visualization Systems) ... Forecast, 2013-2019" the global endoscopy devices market was valued ... to grow at a CAGR of 6.8% from 2013 ... 36.9 billion in 2019. Browse the full ...
(Date:7/10/2014)... , July 11, 2014  Major advances in ... cancer are being highlighted in a three-day Oncology ... from 10-12 July, 2014.  Renowned national and international cancer ... best practices and exchange knowledge on modern technologies ... and efficient. The Summit will ...
(Date:7/10/2014)... DIEGO , July 10, 2014  RESMED INC. (NYSE: ... its fourth quarter and fiscal year ended June 30, 2014 ... Stock Exchange market close. A press release with ResMed,s results ... the company will host a webcast to discuss operating results ... to begin at 1:30 p.m. US Pacific Time and the ...
Breaking Medicine Technology:Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 2Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 4Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 5Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 6Improving quality and access to advanced cancer care in India and South Asia 2Improving quality and access to advanced cancer care in India and South Asia 3Improving quality and access to advanced cancer care in India and South Asia 4Improving quality and access to advanced cancer care in India and South Asia 5ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2
... AVIV, Israel, May 6 InspireMD, developers of,MGuard(TM), announced ... the,iMOS registry. MGuard(TM) was successfully implanted at the General,University ... Jan Horak. , InspireMD plans ... is a post market study, will be conducted in ...
... - Conference Call Today at 5:00 p.m. Eastern Time ... Pharmaceuticals, Inc. (Nasdaq: PARD ), a biopharmaceutical ... the first quarter ended March 31, 2009, and provided ... pivotal Phase 3 SPEAR trial of picoplatin for the ...
Cached Medicine Technology:InspireMD Announces the Enrollment of the 1st Patient in the MGuard iMOS Registry, the Registry Will Enroll 1000 Patients 2InspireMD Announces the Enrollment of the 1st Patient in the MGuard iMOS Registry, the Registry Will Enroll 1000 Patients 3Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update 2Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update 3Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update 4Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update 5Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update 6Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update 7Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update 8Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update 9
(Date:7/11/2014)... (PRWEB) July 11, 2014 Recently, iFitDress.com, ... special occasion outfits, has released its new collection of ... that, the company has announced that all these beautiful ... off. The deadline of the special offer is July ... its major officials pay close attention to customer satisfaction. ...
(Date:7/11/2014)... Organic Crop Farming in ... the limelight over the past decade. According to IBISWorld ... to be an alternative food eaten only by minority ... organic food.” Organic crop farmers have reaped the benefits ... and herbs over the past five years. Industry revenue ...
(Date:7/11/2014)... era of personalized medicine may be just around the ... researcher Min Yu and scientists at Massachusetts General Hospital ... study in Science , Yu and her colleagues ... the blood streams of six patients. Some of these ... travel to and establish secondary tumors in vital organs ...
(Date:7/11/2014)... Alliance Labs announced that they will be featured ... Jr, airing later this year 2014, via Discovery Channel. ... Innovations will explore DocuSol® Kids, a mini-enema containing a ... base designed to give adolescents general constipation relief. Viewers ... hyperosmotic laxative by drawing water into the bowel from ...
(Date:7/11/2014)... Cruciate Ligament (ACL) reconstructions occur more than 200,000 times ... create a new ligament may determine how long you ... today at the Annual Meeting of the American Orthopaedic ... study results highlight that in a young athletic population, ... than using autografts (tissue harvested from the patient)," said ...
Breaking Medicine News(10 mins):Health News:Worldwide Chic Ladies Can Buy Cheap Evening Dresses at iFitDress.com 2Health News:Organic Crop Farming in Australia Industry Market Research Report Now Available from IBISWorld 2Health News:Organic Crop Farming in Australia Industry Market Research Report Now Available from IBISWorld 3Health News:Organic Crop Farming in Australia Industry Market Research Report Now Available from IBISWorld 4Health News:Alliance Labs & DocuSol® to be Featured in Upcoming Episode of Innovations 2Health News:ACL reconstructions may last longer with autografts 2
... efforts to unlock therapeutic potential , , MONDAY, Feb. 9 ... Obama,s anticipated lifting of the eight-year ban on embryonic ... W. Bush. , The anticipation moved one step closer ... House Democrats at a closed-door Virginia retreat a "guarantee" ...
... Inc. (Nasdaq: BNVI ) announced today the ... company,s Scientific Advisory Board. Dr. Gustafsson has extensive experience ... biotech companies. "We are very excited to have Dr. ... advancing our discovery platforms," said Isaac Cohen, O.M.D., Bionovo,s ...
... Fla., Feb. 9 MEDai, Inc., a leading provider ... it is offering a free case study on its ... analytic solution Risk Navigator Clinical(R) and its,application to keep ... The case study explores how one of MEDai,s ...
... -- Mindray Medical,International Limited (NYSE: MR ... devices worldwide, today announced that it will report ... year ended December 31,2008, after the U.S. market ... an earnings conference call at 8:00 AM on ...
... during 2008 holiday shopping seasonFORT WORTH, Texas, Feb. 9 ... customers, raised nearly $1.5 million for the fifth-annual ... fundraising initiative for St. Jude Children,s Research Hospital that ... , Customers who shopped at RadioShack stores had the ...
... supplement is the real deal. Extreme Endurance is a 100% ... certified drug-free by the world,s largest sports drug laboratory. In a ... lactic acid was reduced by 15%. This was a 30 day ... ...
Cached Medicine News:Health News:Scientists Heartened at Prospect of End to Stem Cell Ban 2Health News:Scientists Heartened at Prospect of End to Stem Cell Ban 3Health News:Jan Ake Gustafsson, M.D., Ph.D., Joins Bionovo's Scientific Advisory Board 2Health News:Jan Ake Gustafsson, M.D., Ph.D., Joins Bionovo's Scientific Advisory Board 3Health News:Jan Ake Gustafsson, M.D., Ph.D., Joins Bionovo's Scientific Advisory Board 4Health News:Health Plans Use MEDai to Forecast, Rank Risk and Drive Interventions 2Health News:Mindray to Report Fourth Quarter and Fiscal Year 2008 Financial Results on March 4, 2009 2Health News:RadioShack Helps Raise $1.5 Million for St. Jude Children's Research Hospital(R) Fifth-Annual Thanks and Giving(R) Campaign 2Health News:RadioShack Helps Raise $1.5 Million for St. Jude Children's Research Hospital(R) Fifth-Annual Thanks and Giving(R) Campaign 3Health News:Nutritionist Investigates Claims of New Sports Nutritional Supplement 2Health News:Nutritionist Investigates Claims of New Sports Nutritional Supplement 3Health News:Nutritionist Investigates Claims of New Sports Nutritional Supplement 4Health News:Nutritionist Investigates Claims of New Sports Nutritional Supplement 5
Shepard tying forceps, round curved platform 8 mm, 8.5 cm....
Girard curved tying forceps made of titanium has curved shafts with 8 mm tying platforms, width of shafts 0,25 mm, TCI platforms, round handle, diam. 6 mm, overall length 99 mm....
Girard straight tying forceps made of titanium has straight shafts with 6 mm tying platforms, width of shafts 0,25 mm, TCI platforms, round handle, diam. 6 mm, overall length 105 mm....
Curved tying forceps made of titanium has curved shafts with 6 mm V-grove tying platforms, width of shafts 0,5 mm, TCI platforms, flat handle, width 10 mm, overall length 103 mm....
Medicine Products: